US HB749 | 2017-2018 | 115th Congress
Status
Sponsorship: Slight Partisan Bill (Democrat 16-8-1)
Status: Introduced on January 30 2017 - 25% progression, died in committee
Action: 2017-02-03 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on January 30 2017 - 25% progression, died in committee
Action: 2017-02-03 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Lower Drug Costs through Competition Act This bill amends the Federal Food, Drug, and Cosmetic Act to revise provisions regarding review and approval of generic drug applications or supplements to generic drug applications for drugs: (1) for which there is a shortage, or (2) that have not been recently introduced to the market by more than one manufacturer and for which tentative approval has not been granted to more than two applications. The Food and Drug Administration (FDA) must prioritize the review of such submissions and act on them within 180 days. The FDA may expedite the inspection of a facility proposed to manufacture such a drug. Beginning FY2019, the FDA must award a transferrable generic drug priority review voucher to the sponsor of such an application once the drug has a sustained market presence. A voucher may be used to have the FDA review and take action upon a generic drug application within 180 days of submission. The FDA must establish an additional user fee for applications subject to a voucher. This voucher program is terminated at the start of FY2024. The FDA must periodically report on generic drug applications filed before FY2018 that are still pending. For a new drug application to be eligible for a priority review voucher as a tropical disease product application, the application must include new, essential clinical investigations. The Government Accountability Office must study the FDA's program for drug risk evaluation and mitigation strategies.
Title
Lower Drug Costs through Competition Act
Sponsors
| Rep. Kurt Schrader [D-OR] | Rep. Gus Bilirakis [R-FL] | Rep. Daniel Lipinski [D-IL] | Rep. Seth Moulton [D-MA] |
| Rep. Ami Bera [D-CA] | Sen. Kyrsten Sinema [I-AZ] | Rep. Jim Cooper [D-TN] | Rep. Bill Posey [R-FL] |
| Rep. Jim Costa [D-CA] | Rep. Scott Peters [D-CA] | Rep. Collin Peterson [D-MN] | Rep. Tom O'Halleran [D-AZ] |
| Rep. Brett Guthrie [R-KY] | Rep. Henry Cuellar [D-TX] | Rep. Timothy Walz [D-MN] | Rep. Darren Soto [D-FL] |
| Rep. Sanford Bishop [D-GA] | Rep. Charlie Crist [D-FL] | Rep. Bradley Schneider [D-IL] | Rep. Don Bacon [R-NE] |
| Rep. Jeff Fortenberry [R-NE] | Rep. Jenniffer Gonzalez-Colon [R-PR] | Rep. Josh Gottheimer [D-NJ] | Rep. Greg Gianforte [R-MT] |
| Rep. Stephen Knight [R-CA] |
History
| Date | Chamber | Action |
|---|---|---|
| 2017-02-03 | House | Referred to the Subcommittee on Health. |
| 2017-01-30 | House | Referred to the House Committee on Energy and Commerce. |
| 2017-01-30 | House | Introduced in House |
Same As/Similar To
SB297 (Related) 2017-02-02 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Subjects
Congressional oversight
Drug safety, medical device, and laboratory regulation
Drug trafficking and controlled substances
Government studies and investigations
Health
Infectious and parasitic diseases
Licensing and registrations
Prescription drugs
User charges and fees
Drug safety, medical device, and laboratory regulation
Drug trafficking and controlled substances
Government studies and investigations
Health
Infectious and parasitic diseases
Licensing and registrations
Prescription drugs
User charges and fees
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/115th-congress/house-bill/749/all-info |
| Text | https://www.congress.gov/115/bills/hr749/BILLS-115hr749ih.pdf |
